

Lyka Labs announces Q2FY16 Financial Results Q2FY16 Revenues at INR 307.30 million, EBIDTA at INR 38 million

Mumbai, 12th February, 2016: Lyka Labs Limited, a pharmaceutical company with business across 46 countries globally in super specialty segments of Injections and Dermatology today announced its Financial Results for the second quarter and Half Year ended 31st December 2015.

Financial Results

Q2FY16 (Quarter ended 31st December 2015) – Standalone

- Revenue was at **INR 181.33 million**
- EBIDTA Margin was **24.4%** compared to **22.16%** in Q2FY15, **up 2.24%**
- Finance Cost was **down at INR 34.40 million** compared to **INR 44.91 million** in Q2FY15
- Net Profit was up at **INR 4.41 million** compared to loss of **INR 68.49 million** in Q2FY15

Q2FY16 (Quarter ended 31st December 2015) – Consolidated

- Revenue was at **INR 307.30 million*** compared to INR 358.38 million in Q1FY16
- EBIDTA was at 13.18%
- Finance Cost was **down at INR 45.83 million** in Q2FY16 compared to **INR 57.66 million** in Q2FY15
- Net Profit was up at **INR 5.36* million** compared to **loss of INR 58.30 million** in Q2FY15
- NET PROFIT for the quarter factors one-time transaction fee of **INR 5.38 million** incurred for the sale of Animal Healthcare Business.

**No Sales for Animal Healthcare Business for Q2FY16, as the company has disinvested this business in September 2015.*

H1FY16 (Half Year ended 31st December 2015) - Consolidated

- Revenue was at **INR 661.12* million**
- EBIDTA Margin at **17.13%**
- Finance Cost **down at INR 98.13 million** compared to **INR 116.25 million** in H1FY15
- Net Profit was **up at INR 140.68 million** compared to **INR 4.6 million** in H1FY15

**No Sales for Animal Healthcare Business for Q2FY16, as the company has disinvested this business in September 2015*

Business Review and Strategy

- Export Revenues were higher by 7% over Q1FY16
- Filled 54 Dossiers for Registration in ROW Markets
- Increased Production Capacity for Topical Preparations at Ankleshwar Factory.
- Commissioned new Microbiological Laboratory at Ankleshwar Factory
- Launching Sales & Marketing Department for marketing Dermatology Products in India.

About Lyka Labs Limited

Lyka Labs Limited (BSE-LYKALABS/500259: NSE-LYKALABS) is a leading pharmaceutical company with strong capabilities in Sterile Preparations and Dermatology. It has a wide portfolio of 20+ Lyophilized Products and 50+ products in Dermatology. Its products are marketed across 46 markets globally. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New

Formulations and New Drug Delivery System in its focus areas of Lyophilization and Dermatology and has a portfolio of over 20 products under development

For Queries, Please Contact

Lyka Labs Limited

Yogesh Shah

Chief Financial Officer

Tel: +91 22 66112200

ybshah@lykalabs.com

Piyush Hindia

Company Secretary

Tel: +91 22 66112200

companysecretary@lykalabs.com

Registered Office

Lyka Labs Limited

4801/B & 4802/A

G.I.D.C. Industrial Estate,

Ankleshwar – 393 002

Corporate Information

BSE Code: 500259

NSE Code: LYKALABS

Website: www.lykalabs.com

CIN: L24230GJ1976PLC008738

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances